The SOLAR-1 trial (NCT02437318) demonstrated that the long-term administration of alpelisib plus fulvestrant in HR+/HER2− breast cancer patients with PI3KCA- mutations contributes to improved overall survival (OS). This evidence concerns the gene ERBB2 and breast carcinoma.